Oncology Corporate Profile
Mirna Therapeutics, Inc. (Mirna) is a private biotechnology company focused on the development and commercialization of microRNA (miRNA) based therapeutics. In 2013, the Company was the first to launch a clinical trial of a miRNA mimic drug candidate for the treatment of cancer. Mirna's intellectual property portfolio contains numerous issued patents and patent applications, pertaining to more than 300 miRNAs with applications in oncology and other diseases. Oncology-directed miRNAs include key tumor suppressors in cancer, such as miR-34 and let-7, which inhibited tumor growth in a number of preclinical studies.